{"id":20270,"date":"2022-01-13T10:33:08","date_gmt":"2022-01-13T09:33:08","guid":{"rendered":"https:\/\/idibell.cat\/?p=20270"},"modified":"2022-01-13T10:33:08","modified_gmt":"2022-01-13T09:33:08","slug":"el-cribratge-molecular-en-pacients-amb-cancer-de-mama-avancat-permet-prendre-decisions-terapeutiques-personalitzades","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2022\/01\/el-cribratge-molecular-en-pacients-amb-cancer-de-mama-avancat-permet-prendre-decisions-terapeutiques-personalitzades\/","title":{"rendered":"El cribratge molecular en pacients amb c\u00e0ncer de mama avan\u00e7at permet prendre decisions terap\u00e8utiques personalitzades"},"content":{"rendered":"<p>La revista cient\u00edfica \u201c<a href=\"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.744112\/full\"><em>Frontiers in Oncology<\/em><\/a>\u201d ha publicat recentment els primers resultats de l\u2019estudi pilot AGATA SOLTI-1301\u00a0que tenia com a objectius a<strong>valuar si la implementaci\u00f3 del cribratge molecular en un entorn de vida real era factible<\/strong> i si les pacients podien beneficiar-se d&#8217;un tractament dirigit, en cas de detectar-se alguna mutaci\u00f3.<\/p>\n<p>En aquest estudi hi ha participat <strong>260 pacients amb c\u00e0ncer de mama avan\u00e7at<\/strong> d\u2019arreu de l\u2019Estat. Despr\u00e9s de realitzar-los-hi el cribratge molecular, es va identificar que un 63% d\u2019aquestes pacients tenien alguna mutaci\u00f3 coneguda i en el 50% dels casos el comit\u00e8 d\u2019experts va poder fer una recomanaci\u00f3 de tractament basant-se en els resultats obtinguts.<\/p>\n<p>Finalment, un<strong> 11% d\u2019aquestes pacients s\u2019han beneficiat d&#8217;un tractament dirigit<\/strong>,\u00a0la majoria d\u2019elles a trav\u00e9s d\u2019un assaig cl\u00ednic. D\u2019entre els casos en els quals no es va poder personalitzar el tractament destaquen, principalment, aquells en qu\u00e8 les pacients ja s\u2019havien sotm\u00e8s a una ter\u00e0pia pr\u00e8via.<\/p>\n<p>Per la investigadora principal de l\u2019IDIBELL, cap de la Unitat de C\u00e0ncer de mama de l\u2019ICO l\u2019Hospitalet, membre de SOLTI i primera autora de l\u2019estudi, <strong>S\u00f2nia Pernas<\/strong>, <em>\u201cl\u2019objectiu principal d\u2019aquest estudi era poder avaluar cada cas gr\u00e0cies a la implementaci\u00f3 d\u2019un diagn\u00f2stic molecular i poder identificar la ter\u00e0pia m\u00e9s adequada per a cada pacient en el cas que es detect\u00e9s alguna alteraci\u00f3 amb diana terap\u00e8utica en l\u2019estudi del seu tumor\u201d<\/em>.<\/p>\n<p>&nbsp;<\/p>\n<h4>El primer programa de cribratge molecular en c\u00e0ncer de mama metast\u00e0ic a l\u2019Estat<\/h4>\n<p>L\u2019estudi AGATA est\u00e0 impulsat pel grup de recerca SOLTI, i es tracta del primer programa de cribratge molecular\u00a0en c\u00e0ncer de mama avan\u00e7at creat a l\u2019Estat espanyol. La finalitat de l\u2019estudi era treballar en xarxa amb hospitals de tot l\u2019Estat per tal d\u2019aconseguir que les pacients diagnosticades amb aquest tipus de tumor tinguessin acc\u00e9s a una ter\u00e0pia personalitzada segons el perfil molecular del seu tumor, la majoria mitjan\u00e7ant estudis cl\u00ednics.<\/p>\n<p>Aquest estudi, al qual hi han participat 10 hospitals d\u2019arreu de l\u2019Estat entre ells els tres centres de l\u2019Institut Catal\u00e0 d\u2019Oncologia (l\u2019Hospitalet\/Badalona i Girona), <strong>analitzava els perfils moleculars del tumor de cada pacient<\/strong>, i posteriorment, un comit\u00e8 d&#8217;experts\u00a0 avaluava els resultats per tal d\u2019identificar la ter\u00e0pia m\u00e9s adequada per a cadascuna d\u2019elles.<\/p>\n<p>Per <strong>Pernas<\/strong>, co-investigadora principal de l&#8217;estudi, juntament amb la coordinadora de la Unitat de C\u00e0ncer de Mama i Tumors Ginecol\u00f2gics de l\u2019Hospital 12 de Octubre de Madrid i vicepresidenta de SOLTI <strong>Eva Ciruelos<\/strong>,\u00a0<em>\u201cl\u2019estudi AGATA SOLTI ens ha ajudat a aprendre m\u00e9s de la biologia tumoral del c\u00e0ncer de mama i ha representat el primer pas per tal de poder trencar barreres pel que fa al diagn\u00f2stic molecular. Aix\u00f2 s&#8217;ha vist reflectit en la posada en marxa de l&#8217;estudi HOPE (SOLTI-1903) que empodera a les mateixes pacients amb c\u00e0ncer de mama avan\u00e7at que, a trav\u00e9s d\u2019una eina digital, poden sol\u00b7licitar l\u2019estudi molecular de la seva malaltia a trav\u00e9s de mostres del seu tumor i de sang\u201d.<\/em><\/p>\n<p>L\u2019estudi va comptar amb el suport de Novartis a trav\u00e9s d&#8217;una beca i va ser finan\u00e7at en gran part pel projecte PI 15\/01508, integrat en el Pla Estatal I+D+I i cofinan\u00e7at per l&#8217;Institut de Salut Carles III &#8211; Subdirecci\u00f3 General d&#8217;Avaluaci\u00f3 i el Fons Europeu de Desenvolupament Regional (FEDER) (a la CE) i per una subvenci\u00f3 de la Fundaci\u00f3 M\u00fatua Madrilenya (a la CE).<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><em>L\u2019Institut d&#8217;Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l&#8217;Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l&#8217;Institut Catal\u00e0 de la Salut, l&#8217;Institut Catal\u00e0 d&#8217;Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n<p><em>L\u2019IDIBELL \u00e9s membre del Campus d&#8217;Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L&#8217;any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>L&#8217;estudi va permetre identificar una mutaci\u00f3 coneguda en un 63% de les pacients i un 11% d&#8217;elles van poder beneficiar-se d&#8217;un tractament dirigit basant-se en l&#8217;estudi molecular del seu tumor.<\/p>\n","protected":false},"author":8,"featured_media":20271,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[332,390,447,452],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-05 10:03:49","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/20270"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=20270"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/20270\/revisions"}],"predecessor-version":[{"id":20272,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/20270\/revisions\/20272"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/20271"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=20270"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=20270"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=20270"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}